Derek Small is a seasoned executive with a solid grounding in biotechnology, having served as the CEO of Assembly Biosciences. He took on this role in February 2015 after co-founding Assembly in 2012, leading the company through various stages of...

Derek Small is a seasoned executive with a solid grounding in biotechnology, having served as the CEO of Assembly Biosciences. He took on this role in February 2015 after co-founding Assembly in 2012, leading the company through various stages of development and growth. Small has a BS degree from Franklin College and spent time studying at Harlaxton College in the UK, which highlights his commitment to education. Under his leadership, Assembly focused on cutting-edge research in hepatitis B and microbiome therapies. His salary has grown significantly during his tenure, from $350,000 at the start to $420,000 as he took on more responsibilities. Small's career also includes founding and leading other biotech firms where he made key contributions, which shaped his experience in the rapidly evolving pharmaceutical industry. Interestingly, his insider trading history shows a notable increase in his stock holdings over time, reaching a peak of around $19.56 million before gradually declining. This fluctuation illustrates both the potential and volatility of working in biotech, a field where successes can have substantial financial implications. On a personal note, Derek Small has already demonstrated his ability to adapt and lead through change, especially since he moved on from his CEO role at Assembly in 2019 but continued as a senior advisor. Derek's journey reflects the ups and downs of the biotechnology landscape and emphasizes the importance of innovation in healthcare.